



High-throughput microfluidics  
for strain optimization

Alex Dajkovic, PhD  
Senior Director R&D

*This document gives a non confidential vision of Biomillenia's capabilities and is not intended to be a scientific presentation*



Founded in 2015, revenue generating affiliate of Design Pharmaceuticals




Headquarter in Cambridge, USA  
Laboratories in Cambridge MA (US), Paris area (France), Shanghai (China – in creation)



Proprietary drug discovery platform to discover hit candidates faster and at unprecedented scale





#### Droplet microfluidics platform

- Culturomics (microbiome sourcing, strain isolation, LBPs)
- Ultra-high throughput compound screening




#### GPCR screening platform

- Finding novel GPCR ligands from any source (chemical libraries, antibody libraries etc)
- Global GPCR activity profiling of any biological sample (e.g. clinical trial)




#### Biosynthetic platform

- Building and optimization of valuable APIs
- Lead candidate molecule optimization




Up to 10 000 droplets per second!

Compatible with: bacteria – yeast – microalgae – compounds – human cells



>4000 droplets/s!


- Adding reagents




- Mixing



- Incubating




- Droplets reloading




- Multiple screening rounds



- Droplet merging





Thank you for your attention

Alex Dajkovic  
Senior Director of R&D, Head of Scientific Collaborations  
[a.dajkovic@biomillenia.com](mailto:a.dajkovic@biomillenia.com)